Patient Monitoring & Wearables

SHERIDAN, WYOMING – July 25, 2025 – Philips and Radboud university medical center (Radboudumc) are conducting one of the first large-scale studies to explore the impact of prolonged physical activity on atrial fibrillation, leveraging wearable monitoring technology during the 4Days Marches in the Netherlands. The collaboration combines clinical expertise with cutting-edge sensor technology to better understand how exercise influences this widespread heart rhythm disorder.

Continuous Monitoring for Deeper Insight into Atrial Fibrillation

SHERIDAN, WYOMING – May 27, 2025 – Roche has announced a new strategic collaboration with Broad Clinical Labs, aiming to accelerate the adoption of its next-generation Sequencing by Expansion (SBX) technology, with an initial focus on trio-based whole genome sequencing for critically ill newborns and their biological parents. The partnership signifies a pivotal move in expanding genomics-enabled healthcare and precision medicine at scale.

SHERIDAN, WYOMING – May 27, 2025 – Roche has received FDA approval for Susvimo® (ranibizumab injection) 100 mg/mL as a new treatment for diabetic retinopathy (DR), marking a pivotal advancement in the battle against this vision-threatening condition that affects nearly 10 million Americans.

SHERIDAN, WYOMING – May 9, 2025 – LivaNova PLC, a global leader in medical technology, announced strong first-quarter 2025 results today, demonstrating continued growth and operational efficiency. The company reported high single-digit revenue growth, including double-digit organic revenue increases, as well as expanding operating margins. LivaNova also raised its full-year 2025 revenue guidance, taking into account the impact of the SNIA environmental liability and current tariffs.

SHERIDAN, WYOMING – May 9, 2025 – LivaNova PLC, a leading global medical technology company, has announced 12-month top-line data from its OSPREY clinical trial. The study demonstrates promising results for the aura6000™ System, an investigational device designed to treat moderate to severe obstructive sleep apnea (OSA). The data highlights sustained improvements in key health metrics, positioning the aura6000™ as a potential breakthrough in OSA management.

SHERIDAN, WYOMING – May 8, 2025 – B. Braun Group has demonstrated resilience and strategic growth amidst challenging global conditions, reporting a 4.4% increase in sales for the 2024 fiscal year. The company’s focus on innovation, operational efficiency, and modern technology investments has contributed to a solid financial performance, reaffirming its commitment to advancing healthcare solutions worldwide.

SHERIDAN, WYOMING – May 8, 2025 – GN Store Nord A/S has reported its Q1 2025 financial results, highlighting a mix of challenges and opportunities. The company's growth was impacted by market uncertainties, including global macroeconomic pressures and changes in consumer sentiment, particularly in the U.S. Despite these hurdles, GN has initiated proactive cost mitigation strategies aimed at ensuring long-term profitability and supporting margin growth.

SHERIDAN, WYOMING – May 8, 2025 – Hansaton, a leading name in innovative hearing solutions, has unveiled the Hansaton Essenz platform, introducing the first product in the lineup: sound E-R, a cutting-edge receiver-in-canal (RIC) hearing aid. Designed to provide unparalleled sound quality from the very first use, the sound E-R promises exceptional comfort, reliability, and ease of use. Featuring a sleek, modern design and a convenient magnetic charger, this hearing aid is the perfect companion for those on the go or at home.

SHERIDAN, WYOMING – May7, 2025 – Drägerwerk AG & Co. KGaA has shown significant growth in its order intake during the first quarter of 2025, marking a strong start to the year despite a seasonally weaker operating result. With order intake reaching approximately EUR 861 million, the company exceeded its prior-year figures by EUR 50 million. Net sales closely mirrored last year's numbers, while operating results remained narrowly positive, reflecting both challenges and opportunities across global markets.

SHERIDAN, WYOMING – May 7, 2025 – Resmed Inc. (NYSE: RMD, ASX: RMD), a global leader in connected health solutions for sleep and respiratory care, has announced impressive third-quarter fiscal 2025 results. The company achieved a substantial year-over-year revenue growth of 8%, underscoring the continued demand for its innovative products and digital health solutions. With a focus on operational excellence and expanding its global footprint, Resmed has delivered a strong performance, further solidifying its position as a market leader in the healthcare sector.